Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Research Article

SRP. 2021; 12(3): 809-820


EGFR Inhibitors and Apoptosis Inducers: Design, Docking, Synthesis, and Anticancer Activity of Novel Tri-Chalcone Derivatives

Menier Al-Anazi, Melati Khairuddean, Belal O. Al-Najjar, Mohammad Murwih Alidmat, Nik Nur Syazni Nik Mohamed Kamal, Musthahimah Muhamad, Maywan Hariono.

Abstract
Estrogen receptors (ERs) are primarily expressed in cancer cells and interfere with the epidermal growth factor (EGFR) signal pathway. However, data are limited regarding the interaction between cytoplasmic ER expression and EGFR-tyrosine kinase inhibitor response. The objective of this study was to design multi-target molecules for enhancing anti-cancer activity and decreasing drug resistance. Two distinct series of tri-chalcone derivatives S1(1-7), S2(1-7) with promising anti-cancer activity was incorporated into the current study. Compounds S1(1-2) and S2(1-2) demonstrated the highest binding affinity for interactions with the active EGFR binding site. Interestingly, compounds S1-1 and S1-2 have shown a potent cytotoxicity of MCF-7 (2.23 0.11 and 2.04 0.71 M) and MDA-MB-231 (6.44 0.01 and 3.75 0.26 M), respectively, relative to tamoxifen IC50 of 9.3 0.44 and 18.92 1.43 M. Thus, in-vitro EGFR activity was evaluated for compounds S1-1 and S1-2. The results indicated that compounds S1-1 and S1-2 showed a significant improvement in the anti-cancer resistant treatment due to their potential effects on the EGFR and the possible anti-ER effect.

Key words: Tri-chalcones; EGFR inhibitors; AutoDock; anticancer



Similar Articles

Resetting amino acid metabolism of cancer cells by ATB-targeted nanoparticles for enhanced anticancer therapy.
Kou L, Jiang X, Tang Y, Xia X, Li Y, Cai A, Zheng H, Zhang H, Ganapathy V, Yao Q, Chen R
Bioactive materials. 2022; 9(): 15-28

Redundant roles of EGFR ligands in the ERK activation waves during collective cell migration.
Lin S, Hirayama D, Maryu G, Matsuda K, Hino N, Deguchi E, Aoki K, Iwamoto R, Terai K, Matsuda M
Life science alliance. 2022; 5(1):

Effect of major CYP2C19 genetic polymorphisms on eradication based on different treatment regimens.
Zihlif M, Bashaireh B, Rashid M, Almadani Z, Jarrar Y
Biomedical reports. 2022; 16(1): 2

3D and 4D Tumorigenesis Model for the Quantitative Analysis of Cancer Cell Behavior and Screening for Anticancer Drugs.
Wessels D, Lusche DF, Voss E, Soll DR
Methods in molecular biology (Clifton, N.J.). 2022; 2364(): 299-318

Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD-1 inhibitors.
Jansen P, Lodde GC, Wetter A, Welt A, Stuschke M, Dührsen U, Stoffels I, Klode J, Livingstone E, Zimmer L, Roesch A, Hadaschik E, Griewank KG, Schadendorf D, Ugurel S
Journal of the European Academy of Dermatology and Venereology : JEADV. 2022; 36 Suppl 1(): 41-44


Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Covid-19 Trends and Statistics
ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.



ScopeMed Web Sites